Re-Vana Therapeutics, Ltd. | Belfast, Northern Ireland
Developing state of the art long acting biodegradable drug delivery platform
News: Re-Vana Therapeutics Raises $3.25 Million in Pre-Series A Financing
Dr. Rahhal Interview Re-Vana Therapeutics, Ltd. CEO Michael O'Rourke
Developing state of the art long acting biodegradable drug delivery platform
News: Re-Vana Therapeutics Raises $3.25 Million in Pre-Series A Financing
Dr. Rahhal Interview Re-Vana Therapeutics, Ltd. CEO Michael O'Rourke
LensGen, Inc. | Irvine, California
A biomimetic accommodating intraocular lens
News: LENSGEN® Announces Presentations and SCIENTIFIC Papers AT ESCRS
LensGen Updates on Juvene IOL, adds $15m to Series A
A biomimetic accommodating intraocular lens
News: LENSGEN® Announces Presentations and SCIENTIFIC Papers AT ESCRS
LensGen Updates on Juvene IOL, adds $15m to Series A
Envision Diagnostics, Inc. | Los Angeles, California
Revolutionizing the eye exam
News: Envision Diagnostics raises Series A Financing
Publication: Automated Pupillometry Using a Prototype Binocular Optical Coherence Tomography System
Revolutionizing the eye exam
News: Envision Diagnostics raises Series A Financing
Publication: Automated Pupillometry Using a Prototype Binocular Optical Coherence Tomography System
DTx Pharma. | San Diego, California
Enabling precision medicine by unlocking oligonucleuotide therapeutics.
News: DTx Pharma Completes $10.6 Million Series A Financing
Enabling precision medicine by unlocking oligonucleuotide therapeutics.
News: DTx Pharma Completes $10.6 Million Series A Financing
ONL Therapeutics, Inc. | Ann Arbor, Michigan
Pioneering an entirely new approach to preserving sight
News: ONL Therapeutics Announces First Patient Treated in Phase I Study With ONL1204
ONL Therapeutics Announces First-in-human Clinical Study With ONL1204
ONL Therapeutics Raises $3 Million in a Convertible Note to Advance ONL1204
Pioneering an entirely new approach to preserving sight
News: ONL Therapeutics Announces First Patient Treated in Phase I Study With ONL1204
ONL Therapeutics Announces First-in-human Clinical Study With ONL1204
ONL Therapeutics Raises $3 Million in a Convertible Note to Advance ONL1204
Trefoil Therapeutics, Inc. | San Diego, California
Developing novel compounds to treat corneal dystrophies
News: Trefoil Therapeutics Appoints Thomas M. Tremblay, RN BSN, Vice President, Clinical Development
Trefoil Therapeutics Raises $5.2 Million Series 1 Financing
Developing novel compounds to treat corneal dystrophies
News: Trefoil Therapeutics Appoints Thomas M. Tremblay, RN BSN, Vice President, Clinical Development
Trefoil Therapeutics Raises $5.2 Million Series 1 Financing
2C Tech Corporation, Inc. | Irvine, California
Quantum Dots to treat retinal disease
Studies: Library
Quantum Dots to treat retinal disease
Studies: Library
Qura, Inc. | Boston, Massachusetts
Implantable intraocular pressure sensor
News: Qura receives strategic investment from Santen Ventures
Implantable intraocular pressure sensor
News: Qura receives strategic investment from Santen Ventures
RetroSense Therapeutics, LLC | Irvine, California
(Acquired: Allergan) First in class optogenetics therapy to treat retinal diseases
News: Allergan Acquires Gene Therapy Company RetroSense Therapeutics
(Acquired: Allergan) First in class optogenetics therapy to treat retinal diseases
News: Allergan Acquires Gene Therapy Company RetroSense Therapeutics